An open-label extension of the international Adapt trial, Adapt+ involved 151 adults with generalized autoimmune myasthenia gravis treated with cycles of four weekly infusions of Vyvgart® (efgartigimod) over three years, according to a dosage schedule adapted to the course of the disease. After an average of 18 months of treatment and follow-up, the investigators noted :
- a clinically significant improvement in MG-ADL and QMG scores, as early as one week after the first infusion;
- at least one treatment-related adverse event in 84.8% of participants, most commonly headache (24.8%), Covid-19 (15.2%) or nasopharyngitis (13.8%).
